Skip to main content
MedVellum
MCQsExamsAtlas
DashboardPricing
MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳

MedVellum.

The folio

Exam-exhaustive medical education across every specialty — evidence-graded topics, engraved plates, and practice in every written and oral format. Educational content only — not medical advice.

llms.txt · psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship
  • Paediatrics Fellowship
  • Physician Medicine

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Folio edition · Set in Instrument Serif & Archivo

Paeds SAQsgenetics-dysmorphology-and-metabolism

Paeds SAQs · genetics-dysmorphology-and-metabolism

Mucopolysaccharidoses and oligosaccharidoses — formative SAQs

Formative SAQs on the mucopolysaccharidoses and oligosaccharidoses: recognising the coarse-facies phenotype with dysostosis multiplex, grouping the subtypes by stored substrate and the discriminating cornea-versus-intellect signs, confirming with a layered urine-and-enzyme-and-genotype workup, and matching the disease-modifying therapy to central-nervous-system involvement.

20 marks30 min
On this page & tools

Target exams

RACP General PaediatricsRACP DWEMRCPCH Clinical

Target exams

RACP General PaediatricsRACP DWEMRCPCH Clinical
Prompt
Mucopolysaccharidoses and oligosaccharidoses across infancy and childhood

Question 1 (10 marks)

A three-year-old boy who appeared normal at birth is referred for progressive coarsening of the facial features, persistent umbilical hernia, snoring, and slowing of speech. Examination reveals macroglossia, hepatosplenomegaly with the liver edge 4 cm below the costal margin, claw-hand deformity, and a thoracolumbar gibbus. A skeletal survey shows dysostosis multiplex. The cornea is clear and he is a boy. [1] [2]

(a) Give the most likely disorder family and the single most discriminating bedside feature pointing to the subtype, justifying why the clear cornea matters. (3 marks) [1]

(b) Outline the stepwise confirmatory investigation strategy, naming the first-line screening test, the confirmatory enzyme test, and the molecular test, and explain how the urinary glycosaminoglycan pattern is used. (4 marks) [1] [2]

(c) Explain why the treatment modality depends on whether the central nervous system is involved, naming the two principal disease-modifying options and the constraint on each. (3 marks) [2] [3]

Question 2 (10 marks)

A six-month-old who had been developing normally now has a coarse face, striking gingival hyperplasia, restricted joints, and cardiomegaly. Laboratory testing reveals that several plasma lysosomal enzyme activities are markedly elevated rather than deficient, while cultured fibroblast enzyme activities are low. [2]

(a) Give the unifying diagnosis and explain the paradox of the elevated plasma enzymes in one sentence. (3 marks) [2]

(b) Contrast this disorder's prognosis and management with that of severe Hurler syndrome (MPS I), naming the disease-modifying option that has transformed Hurler outcome and the timing constraint that governs it. (4 marks) [2] [4]

(c) A four-year-old with severe hyperactivity, aggression, sleep reversal, and only mild coarsening is referred. Name the likely subtype and explain why the parents' presenting complaint is behavioural rather than somatic. (3 marks) [1] [2]

References

  1. [1]Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford), 2011.PMID 22210669
  2. [2]Wraith JE. Mucopolysaccharidoses and mucolipidoses. Handb Clin Neurol, 2013.PMID 23622395
  3. [3]Muenzer J, Gucsavas-Calkoglu M, McCandless SE, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med, 2006.PMID 16912578
  4. [4]Gentner B, Spinozzi G, Cordes S, et al. Hematopoietic stem- and progenitor-cell gene therapy for Hurler syndrome. N Engl J Med, 2021.PMID 34788506